<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620268</url>
  </required_header>
  <id_info>
    <org_study_id>CK2012-001</org_study_id>
    <nct_id>NCT01620268</nct_id>
  </id_info>
  <brief_title>An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria</brief_title>
  <official_title>An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changzheng-Cinkate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changzheng-Cinkate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical efficacy and safety of a combination of leflunomide and
      orotic acid in kidney transplant patients with high levels of Polyoma BK viruria for the
      purpose of preventing Polyoma BK viremia and Nephropathy that could lead to kidney transplant
      loss from viral damage, acute rejection or both.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized trial that will evaluate the effect of a combination of
      leflunomide and orotic acid for the treatment of Polyoma BK viruria. In this multicenter
      trial, renal allograft patients with the diagnosis of Polyoma BK viruria as determined by a
      viral level in the urine of 25 million or more copies/mL, and no detectable viremia, will
      complete a screening visit (V1) to determine eligibility for the study based on
      inclusion/exclusion criteria. Patients that meet the entrance criteria for this study will be
      randomly assigned to one of two treatment groups at Visit (2) and enter a 4 month dosing
      period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of viruria</measure>
    <time_frame>12 weeks</time_frame>
    <description>Viral load of Polyoma BK virus in urine reduced from greater than or equal to 10 million copies/mL to less than 500,000 copies/mL or a 2 log reduction in copies/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of viremia</measure>
    <time_frame>12 weeks</time_frame>
    <description>No more that 1000 copies of Polyoma BK Virus in the blood on two consecutive tests 2 weeks or more apart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Polyoma BK Nephropathy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absence of Polyoma BK Nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No rejection of the renal allograft</measure>
    <time_frame>12 weeks</time_frame>
    <description>No rejection of the renal allograft</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Viruria</condition>
  <condition>Viremia</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose adjusted leflunomide plus 600 mg orotic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide and orotic acid</intervention_name>
    <description>Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients, 75 years of age or less, with the diagnosis of renal allograft Polyoma BK
             viruria of 10 million or more copies/mL in their urine confirmed by PCR at the central
             laboratory.

          2. No viremia (viremia is defined as greater than 1,000 copies/ml plasma on two
             consecutive tests two weeks or more apart as measured at the designated central
             laboratory),

          3. Serum creatinine &lt;2.0 mg/dL

          4. Hct &gt; 30%

          5. WBC &gt; 3,500 x 103/L

          6. Platelet count &gt; 150,000 x 103/L

          7. Normal values for ALT, AST and bilirubin; Alk Phos &lt; 2 X upper limits of normal

          8. No symptomatic cardiac, pulmonary, GI, hepatic or neurologic disease

          9. No other active infections

         10. Receiving CyA or Tacrolimus, Mycophenolate/Azathioprine + prednisone.

         11. Is not pregnant as verified by a pregnancy test

        Exclusion Criteria:

          1. Is not able to comply with study procedures and dosing.

          2. Has psychiatric instability.

          3. Has an active systemic infection including Hepatitis B or C, HIV, or on anti-viral
             therapy within seven days of entering the study. Note however, that the subjects may
             be taking ganciclovir, valaciclovir, acyclovir and valganciclovir and therefore these
             are not exclusionary antiviral medications.

          4. Has BK viremia (viremia is defined as greater than 1,000 copies/ml plasma on two
             consecutive tests two weeks or more apart as measured at the designated central
             laboratory), or has had a single episode of BK viremia. (viremia is defined as greater
             than 1,000 copies/ml plasma on two consecutive tests two weeks or more apart as
             measured at the designated central laboratory or the local laboratory),

          5. Has a cancer diagnosis within past five years with potential for recurrence.

          6. Has received experimental drug within past 3 months.

          7. Is receiving immune suppressive drug other than those listed above calcineurin
             inhibitor, mycophenolate/azathioprine and +/- corticosteroid)

          8. Is a woman of child bearing potential or is a male with female partner of child
             bearing potential who is unwilling to use reliable contraception.

          9. Has any neurologic abnormalities including peripheral neuropathy.

         10. Is receiving concomitant therapy with drug known to have hepatotoxic risk.

         11. Has known or suspected liver disease or current alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cinkate Corp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James W. Williams, MD</last_name>
    <phone>7734263209</phone>
    <email>jameswarrenwilliams@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James L Yeager, PhD</last_name>
    <phone>8472839176</phone>
    <email>james_yeager@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Ayer, BS,CCRP</last_name>
      <phone>205-996-2577</phone>
      <email>tayer@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Clifton Kew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Fernandez, RN</last_name>
      <phone>813-844-5692</phone>
      <email>debbiefernandez@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Rajendra Baliga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush Univeristy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherese Pullum, BSN</last_name>
      <phone>312-563-4249</phone>
      <email>pullum@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Hollinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Thielke, PharmD</last_name>
      <phone>312-996-5695</phone>
      <email>pwest@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Ignatus Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Transplant Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Lockwood, MSN, RN</last_name>
      <phone>773-834-0684</phone>
      <email>mlockwood@surgery.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle Josephson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Ponsler-Sipes</last_name>
      <phone>317-944-7580</phone>
      <email>kmponsle@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Tim Taber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Lousiville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne M Webb, RN, BSN</last_name>
      <phone>502-587-4106</phone>
      <email>anne.webb@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Eng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosmary Ouseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M McDermott, RN, MPH</last_name>
      <phone>617-632-9841</phone>
      <email>smcderm2@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Martha Pavlakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol B Jones, RN, BSN</last_name>
      <phone>901-516-8078</phone>
      <email>carol.jones@mlh.org</email>
    </contact>
    <investigator>
      <last_name>Vinaya Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leflunomide</keyword>
  <keyword>orotic acid</keyword>
  <keyword>Polyoma BK Viruria</keyword>
  <keyword>Polyoma BK Viremia</keyword>
  <keyword>Polyoma BK Nephropathy</keyword>
  <keyword>Renal Allograft Rejection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

